Summary:
- The article discusses the development of a new COVID-19 vaccine candidate by Bharat Biotech, an Indian biopharmaceutical company.
- The vaccine, known as BBV154, is a nasal vaccine that is being developed as a potential intranasal booster dose for individuals who have already received other COVID-19 vaccines.
- The article highlights the advantages of a nasal vaccine, such as the potential for better immune response and ease of administration, as well as the ongoing clinical trials and the company's plans for further development and regulatory approvals.